SCHEDULE: Altium Capital Divests Entire Sunshine Biopharma Stake
Schedule 13G Amendment
Altium Capital Management LLC and its affiliates have reported a 0% beneficial ownership in Sunshine Biopharma, Inc. common stock, indicating a full divestment of their previous holdings.
Summary
- Altium Capital Management LLC, Altium Healthcare Long Short Onshore Fund LP, and Altium Healthcare Long Short GP LLC (collectively, "Altium") have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates that Altium's aggregate beneficial ownership in Sunshine Biopharma, Inc. common stock is now 0%.
- This represents a complete divestment of their previously reported stake in the company.
- The event requiring this filing occurred on June 30, 2025.
Sentiment
Score: 3
Explanation: The complete divestment of an institutional investor's stake in Sunshine Biopharma, Inc. is generally viewed as a negative signal, potentially indicating a lack of confidence or a shift in investment strategy away from the company. While the filing provides no reasons, the action itself is a bearish indicator for the issuer.
Negatives
- A significant institutional investor, Altium Capital, has fully divested its stake in Sunshine Biopharma, Inc., reducing its beneficial ownership to 0%.
Future Outlook
No forward-looking statements or guidance are provided in this ownership disclosure filing.
Industry Context
This filing reflects a change in an institutional investor's portfolio allocation, which is a common occurrence in the financial markets. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: May react negatively to the news of a significant institutional investor fully divesting its stake, potentially leading to downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement, indicating the point at which beneficial ownership changed to 0%. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 1 was signed by Altium Capital Management LLC and its affiliates. |
Keywords
Sunshine Biopharma, Altium Capital Management, Altium Healthcare, Schedule 13G, beneficial ownership, common stock, divestment, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.